Medicine guide
Lumoxiti
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Moxetumomab pasudotox
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Moxetumomab pasudotox |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01X · Cancer treatments and immune-system medicines |
| Authorised on | 2021-02-08 |
| Last updated by the regulator | 2021-08-11 |
| EMA product number | EMEA/H/C/005322 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).